Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,665 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.
Wei X, Zou Z, Zhang W, Fang M, Zhang X, Luo Z, Chen J, Huang G, Zhang P, Cheng Y, Liu J, Liu J, Zhang J, Wu D, Chen Y, Ma X, Pan H, Jiang R, Liu X, Ren X, Tian H, Jia Z, Guo J, Si L. Wei X, et al. Among authors: zou z. Eur J Cancer. 2024 May;202:114008. doi: 10.1016/j.ejca.2024.114008. Epub 2024 Mar 11. Eur J Cancer. 2024. PMID: 38479118 Clinical Trial.
Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study.
Cui C, Chen Y, Luo Z, Zou Z, Jiang Y, Pan H, Fan Q, Zhao J, Xu Q, Jiang R, Wang X, Ma T, Guo Z, Si L, Chi Z, Sheng X, Dou Y, Tan Q, Wu D, Guo J. Cui C, et al. Among authors: zou z. BMC Cancer. 2023 Feb 6;23(1):121. doi: 10.1186/s12885-022-10473-y. BMC Cancer. 2023. PMID: 36747118 Free PMC article. Clinical Trial.
Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma.
Zhao L, Ren Y, Zhang G, Zheng K, Wang J, Sha H, Zhao M, Huang R, Kang D, Su X, Wu Y, Zhang W, Lai R, Li L, Mei R, Wang Y, Tian Y, Wang F, Liu B, Zou Z. Zhao L, et al. Among authors: zou z. J Immunother Cancer. 2024 Jun 21;12(6):e008611. doi: 10.1136/jitc-2023-008611. J Immunother Cancer. 2024. PMID: 38908858 Free PMC article. Clinical Trial.
The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases.
Ren Y, Lv Q, Yue W, Liu B, Zou Z. Ren Y, et al. Among authors: zou z. Melanoma Res. 2020 Feb;30(1):85-101. doi: 10.1097/CMR.0000000000000620. Melanoma Res. 2020. PMID: 31095042
4,665 results